Transatlantic Comparison of Pediatric Continuous Glucose Monitoring use in the DPV Initiative and T1D Exchange Quality Improvement Collaborative

Achieving glycemic targets in youth and young adults with type 1 diabetes is challenging. Diabetes devices including continuous glucose monitors (CGM) may impact glycemic control. We analyzed the proportion of CGM use in youth and young adults with type 1 diabetes at nine U.S. T1D Exchange QI Collaborative (T1DX-QI) centers and 402 European diabetes prospective follow-up registry (Diabetes-Patienten-Verlaufsdokumentation (DPV)) sites from 2017-2020 and examined the association of CGM use to glycemic control as measured by hemoglobin A1c. CGM use increased each year from 2017 to 2020 across all age ranges (<6, 6-<12, 12-<18, 18-<25 years) in both registries and lower mean HbA1c was observed in CGM users compared to non-users regardless of insulin delivery method for all years analyzed. CGM use appeared to increase more so in the European DPV than the U.S. T1DX-QI which may be due to transatlantic differences in healthcare systems, insurance coverage, and prescriber habits.